NivolumabPsoriasis following an off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1717卷 / 1期

关键词：

D O I：

10.1007/s40278-018-51284-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：214 / 214

相关论文

共 50 条

[21] MethylprednisoloneFungaemia following an off-label use: case report
Reactions Weekly, 2022, 1899 (1) : 243 - 243
[22] SirolimusPneumonia following off-label use: case report
Reactions Weekly, 2020, 1800 (1) : 269 - 269
[23] ClonazepamMisidentification following off-label use: case report
Reactions Weekly, 2022, 1926 (1) : 171 - 171
[24] RituximabAgranulocytosis following off-label use: case report
Reactions Weekly, 2018, 1712 (1) : 482 - 482
[25] InsulinHypoglycaemia following off-label use: case report
Reactions Weekly, 2021, 1843 (1) : 204 - 204
[26] GalcanezumabConstipation following off-label use: case report
Reactions Weekly, 2025, 2046 (1) : 169 - 169
[27] BevacizumabCataract following off-label use: case report
Reactions Weekly, 2019, 1747 (1) : 63 - 63
[28] SirolimusNeutropenia following off-label use: case report
Reactions Weekly, 2023, 1960 (1) : 394 - 394
[29] RisperidonePancreatitis following off-label use: case report
Reactions Weekly, 2022, 1934 (1) : 378 - 378
[30] TemozolomideThrombocytopenia following off-label use: case report
Reactions Weekly, 2025, 2040 (1) : 934 - 934

← 1 2 3 4 5 →